Kaneka Eurogentec Receives GMP Accreditation for New mRNA Manufacturing Facility – COVID-19 Vaccine Production Ongoing
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217005028/en/
A new GMP facility for active pharmaceutical ingredient production
The new facility audited and accredited by Belgian Authorities will allow the production and the purification of up to 10 g scale ( up to 1 Million doses of vaccine) of RNA for use in human clinical trials and commercial supply, with potential for expansion.
Strengthening Eurogentec’s position as a leader in gene therapy
Dr. Lieven Janssens, Kaneka Eurogentec’s President and CEO, said , “Manufacturing GMP mRNA complements perfectly our ongoing GMP DNA manufacturing activities providing a one-stop-shop offering Plasmid DNA, linearization and mRNA production.
It’s definitely the ambition of Kaneka Eurogentec to become the world leading CDMO for mRNA, as we are already for the production of plasmid DNA.”.
Two mRNA contracts already signed
The expertise of the company for more than 25 years as CDMO for the manufacturing of GMP Biopharmaceuticals is recognized worldwide. Two customers have already signed for three mRNA sequences including for early phase COVID-19 clinical trials.
About Kaneka Eurogentec
Eurogentec was founded in 1985 as one of the first biotech companies in Belgium. Kaneka Eurogentec contributes to improving health and fighting diseases by supplying products and services to scientists involved in life science research, molecular diagnostics, and therapeutic developments. The Liège-based company is recognised as one of the major suppliers in the field of genomics and proteomics as well as a trusted Contract Development and Manufacturing Organisation (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines
In 2010, Eurogentec, renamed Kaneka Eurogentec in April 2017, became part of Kaneka Corporation, a large Japanese chemical company focusing on technology and innovation.
About Kaneka Corporation
Kaneka is an innovation-oriented chemical company. Traditionally the company has been active in polymers, fermentation, biotechnology and electronics, as well as other fields. Business activities now span a broad spectrum of markets ranging from plastics, EPS resins, chemicals and foodstuffs to pharmaceuticals, medical devices, electrical and electronic materials and synthetic fibers. The life science related activities are currently one of the strategically important domains for Kaneka. The company has been a pioneer among Japanese chemical companies in establishing overseas operations, beginning in 1970 with a subsidiary in Belgium.
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-VERIMATRIX1.3.2021 17:47:11 CET | Press release
Verimatrix’s Lu Bolden To Speak on Latest Video Piracy Trends During SportsPro OTT Summit USA
VA-DEQUE-SYSTEMS1.3.2021 17:02:06 CET | Press release
Deque Systems Launches axe DevTools Pro
CGTN1.3.2021 16:07:12 CET | Press release
CMG Chief: 'Ancient Chinese Literature' TV Show Reveals Nation's Soul
WA-AUTH01.3.2021 15:02:14 CET | Press release
Auth0 Names Jameeka Green Aaron as Chief Information Security Officer
CA-C3.AI1.3.2021 15:02:14 CET | Press release
Former SAP Co-CEO Jim Snabe Joins C3 AI Board of Directors
MOODY’S-ANALYTICS1.3.2021 14:50:12 CET | Press release
Moody’s Analytics Wins Five InsuranceERM Awards
LFB1.3.2021 14:02:06 CET | Press release
LFB Announces that the European Medicines Agency (EMA) Has Accepted for Filing the Marketing Authorization Application for eptacog beta (activated), a Recombinant Coagulation Factor VIIa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom